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Abstract
Background: Experience suggests that patients with alcohol and other drug use disorders (AOD)
are commonly cared for in our intensive care units (ICU's) and require more sedation. We sought
to determine the impact of AOD on sedation requirement and mechanical ventilation (MV)
duration.
Methods: Retrospective review of randomly selected records of adult patients undergoing MV in
the medical ICU. Diagnoses of AOD were identified using strict criteria in Diagnostic and Statistical
Manual of Mental Disorders, and through review of medical records and toxicology results.
Results: Of the 70 MV patients reviewed, 27 had AOD (39%). Implicated substances were alcohol
in 22 patients, cocaine in 5, heroin in 2, opioids in 2, marijuana in 2. There was no difference
between AOD and non-AOD patients in age, race, or reason for MV, but patients with AOD were
more likely to be male (21 versus 15, p < 0.0001) and had a lower mean Acute Physiology and
Chronic Health Evaluation II (22 versus 26, p = 0.048). While AOD patients received more
lorazepam equivalents (0.5 versus 0.2 mg/kg.day, p = 0.004), morphine equivalents (0.5 versus 0.1
mg/kg.day, p = 0.03) and longer duration of infusions (16 versus 10 hours/day. medication, p =
0.002), they had similar sedation levels (Richmond Agitation-Sedation Scale (RASS) -2 versus -2, p
= 0.83), incidence of agitation (RASS ≥ 3: 3.0% versus 2.4% of observations, p = 0.33), and duration
of MV (3.6 versus 3.9 days, p = 0.89) as those without AOD.
Conclusion: The prevalence of AOD among medical ICU patients undergoing MV is high. Patients
with AOD receive higher doses of sedation than their non-AOD counterparts to achieve similar
RASS scores but do not undergo longer duration of MV.
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Background
Sedative and opioid agents are routinely administered to
critically ill patients to treat agitation and facilitate
mechanical ventilation (MV) [1]. Appropriate use of these
agents is important as severe agitation is associated with
prolonged MV and increased risk of self-extubation [2].
Excessive sedation administration is also associated with
prolonged MV, and strategies aimed to limit oversedation
have been found to decrease MV duration [3-7].
Alcohol and other drug use disorders (AOD) affect 9.4%
of the American population, and prevalence of these dis-
orders in intensive care units (ICU's) ranges from 5 to
30% [8-11]. Unlike patients without AOD, evidence sug-
gests that patients with AOD on MV may develop with-
drawal syndromes if undersedated or with early
withdrawal of sedation, and sedative agents have been
found to reduce the duration of alcohol withdrawal delir-
ium [12,13]. However, the sedative requirements of
patients with AOD have not been studied extensively.
Because there has been an increased focus recently on
minimizing sedation to improve MV outcomes, and
because patients with AOD may require a different
approach to sedation while on MV, we designed a study to
determine the prevalence of AOD and sedation needs
among our medical ICU patients undergoing MV. We
hypothesized that patients with AOD would require
higher doses of sedatives and opioids, have more episodes
of agitation, and require a longer duration of MV than
those without AOD. The results of this study have previ-
ously been published in abstract form [14].
Methods
The study was conducted in accordance with the ethical
standards of the Virginia Commonwealth University's
Office of Research Subject Protection and the Declaration
of Helsinki of 1975, as revised in 1983. The study was
approved by Virginia Commonwealth University Office of
Research Subject Protection, Richmond, Virginia, and the
need for consent was waived. The study was a retrospec-
tive cohort study of patient medical records. Medical
patients admitted to our medical ICU who required inva-
sive MV were eligible for study participation. The medical
ICU is a closed unit where patients have similar surround-
ings. All beds are located in close proximity to nursing sta-
tions and medical equipment. When monitoring
equipment alarms, the alarm not only sounds at the nurs-
ing stations but also in all patient rooms. Only patients
physically located in the medical ICU were eligible for
study participation thereby assuring that the noise expo-
sure was similar for all study patients.
Using a random number generator, patients were selected
from a list of all patients undergoing MV in our medical
ICU between October 2002, and June 2003. Study exclu-
sion criteria were age<18 years, duration of MV<24 hours
(to exclude those who required a short course of intuba-
tion for overdose), tracheostomy at the time of initiation
of MV, transfer from another ICU service, location other
than our medical ICU, or prisoners. If patients had multi-
ple courses of MV during their hospitalization, only the
first episode was evaluated. Sedation was managed
according to our medical ICU algorithm and based on
published recommendations [5,15]. The sedation algo-
rithm goals were to maximize the use of boluses, to mini-
mize the duration of continuous intravenous infusion of
sedation, and to treat pain with opioids. Weaning from
MV was also standardized through the use of daily spon-
taneous breathing trials and was guided by bedside
Nurses, Respiratory Therapists and Physicians [16].
AOD was classified according to the substance used: alco-
hol, benzodiazepines or barbiturates, heroin, opioids
(other than heroin), cocaine, amphetamines, marijuana
and other (excluding nicotine). Diagnosis of AOD was
assigned if the disorder was present within one year previ-
ous to initiation of MV. Medical records were reviewed for
the target admission as well as previous admissions and
outpatient visits. To maximize diagnostic accuracy,
experts in Addiction Medicine and Psychiatry assigned the
diagnosis (MFW, JT). Diagnosis was established through
review of toxicology results, medical records, and based
on the Diagnostic and Statistical Manual of Mental Disor-
ders, 4th Edition TR (DSM IV-TR) (Table 1) [17].
• Medical record: When physician notes explicitly docu-
mented the presence of alcohol or drug abuse, depend-
ence, and/or addiction, the patient was classified as
having AOD. When the terms abuse, dependence or
addiction were not documented in the record, the patient
was not diagnosed with AOD based on review of medical
records alone.
￿ Clinical diagnosis: Definitions of substance dependence
and substance abuse as defined in DSM IV-TR are outlined
in Table 1. If details in the medical history permitted,
patients were diagnosed with AOD. For example, patients
who presented to the Emergency Department with trauma
and intoxication were diagnosed with AOD. As another
example, patients with a history of withdrawal syndromes
while on the inpatient ward were diagnosed with AOD. As
a third example, patients with history of alcoholic cirrho-
sis who had consumed alcohol within the previous year
were diagnosed with AOD.
￿ Toxicology results: If these revealed the presence of
cocaine, heroin, marijuana, or amphetamine, patients
were considered to have AOD. Patients with toxicology
results that were positive for other opioids, benzodi-BMC Anesthesiology 2007, 7:3 http://www.biomedcentral.com/1471-2253/7/3
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azepines, or barbiturates were diagnosed with AOD if the
substances were not administered by a healthcare profes-
sional prior to collection of urine or blood samples. Posi-
tive toxicology results for alcohol could be used only if
they supported a clinical diagnosis (e.g. alcohol with-
drawal syndromes, alcoholic cirrhosis), and could not be
used in isolation.
Investigators who collected the remaining data (MdW,
SYW, SG, WIJ) were blinded to the diagnosis of AOD.
Similarly, Addiction Medicine (MFW, JT) experts were
blinded to the remaining data.
Baseline characteristics of age, gender, race, ethnicity, rea-
son for MV (which is also the reason for ICU admission
and the major diagnosis), ratio of partial pressure of oxy-
gen to fraction of inspired oxygen (P/F) positive end expir-
atory pressure (PEEP), and Acute Physiology Chronic
Health Evaluation II (APACHE II) were collected [18].
Because AOD patients may present with altered menta-
tion, we adjusted APACHE II for Glasgow Coma Score
(GCS; adjusted APACHE II = APACHE II - (15 - GCS))
[19]. Sequential Organ Failure Assessment (SOFA) was
computed for the first day of MV and was also adjusted for
GCS (adjusted SOFA = Respiratory score + Platelet score +
Bilirubin score + Hypotension score + Renal score) [20].
The total amount of sedatives and opioids administered
during the course of MV was calculated, and duration of
continuous intravenous infusion was recorded. Benzodi-
azepines and barbiturates were converted to lorazepam
equivalents, and opioids were converted to morphine
equivalents using referenced conversion formulas
[21,22]. Dose of propofol was also recorded and not con-
verted to lorazepam equivalents because of unavailability
of published data. We limited analysis to sedative and
opioid administration with abuse potential and therefore
did not record administration butyrophenones and phe-
nothiazines. Sedation depth using Richmond Agitation-
Sedation Scale (RASS, Table 2), as routinely recorded by
nursing staff every 4 hours, was collected [23]. Duration of
MV, reintubation within 72 hours of extubation,
unplanned extubation, placement of tracheostomy, ICU
mortality, hospital mortality, hospital length of stay and
ICU length of stay were recorded.
Data analysis
The primary aim compares patients with AOD to those
without AOD. Duration of MV was computed using Kap-
lan-Meier method and compared by log rank. Normally
distributed data were compared using two-group t-test.
Non-normally distributed data were compared using Wil-
coxon Test. A mixed-model repeated-measures ANOVA
was used to compare sedation levels. The prevalence of
AOD in the study was compared to that of the city of Rich-
mond, Virginia (17.9%), using Chi-square [24]. ICU and
hospital mortality rates as well as reintubation and trache-
ostomy rates were compared using Chi-square or Fisher's
Exact test when appropriate. ICU and hospital length of
stay were compared using log rank. Alpha was set at 0.05.
Normally distributed data are reported as mean and 95%
confidence interval (CI), and non-normally distributed
data as median and interquartile range (IQR), or median
and 95% CI.
Sample size calculation
We had a priori estimated the proportion of patients with
AOD to be 30–40%. Study primary endpoint was total
dose of sedative and total dose of opioids administered.
Power analysis indicated that with 70 patients, we would
be able to detect a 0.7 standard deviation difference with
80% power and a 0.85 standard deviation with 90%
power.
Table 1: Definition of Substance Dependence and Substance Abuse
Substance dependence is manifested by three or more of the following:
(i) tolerance, as marked by the need for larger doses to achieve intoxication or desired effect or markedly diminished effect with continued use of 
the same amount of substance;
(ii) development of withdrawal symptoms or use of substance to relieve or avoid withdrawal symptoms;
(iii) taking larger amounts or over longer periods than intended;
(iv) persistent desire or unsuccessful efforts to cut down or control substance use;
(v) spending time obtaining the substance, using the substance or recovering from its effects;
(vi) performing important social, occupational or recreational activities less frequently because of the substance;
(vii) continuing use of the substance despite knowledge of adverse physical or psychological problems.
Substance abuse is manifested by at least one of the following:
(i) recurrent use resulting in failure to fulfill major obligations at work, home or school;
(ii) recurrent use in situations in which it is physically hazardous;
(iii) recurrent substance-related legal problems;
(iv) continued use despite having persistent or recurrent social or interpersonal problems.BMC Anesthesiology 2007, 7:3 http://www.biomedcentral.com/1471-2253/7/3
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Results
Three hundred fifty-three patients requiring MV were
admitted to the medical ICU between October 2002 and
June 2003. One hundred forty-nine patients selected by
the random number generation algorithm were screened.
Seventy-nine patients failed to meet the pre-specified
inclusion criteria for the following reasons: age<18 years
(1), duration of MV<24 hours (22), tracheostomy at the
time of initiation of MV (2), transfer from another ICU
(20), location other than medical ICU (24), prisoner (10).
Of the 70 patients meeting the inclusion criteria, 27
(39%) were diagnosed with AOD (Figure 1). The diagno-
sis of AOD was established based on toxicology results in
5 (19%), identification by the healthcare provider in the
medical record in 16 (59%), and by the DSM IV-TR crite-
ria in 7 (26%) patients. Of the 21 patients who underwent
toxicology screens, 1 was positive for alcohol, 4 for
cocaine, 5 for benzodiazepines, and 7 for opiates. All pos-
itive benzodiazepine and opiate screens could be
accounted for by administration of medication prior to
sample acquisition. No toxicology screen was positive for
amphetamine, barbiturate, or cannabis.
Overall, alcohol was implicated in 22 cases (31%) and
other drugs in 7 (10%). Of the 22 patients with alcohol
use disorders, alcohol was the only implicated substance
in 20 (91%) cases, while 2 patients had other drug use dis-
orders (marijuana in 1 case and cocaine, opioids and mar-
ijuana in the second case). Of the 7 patients with other
drug use disorders, heroin and/or cocaine were implicated
in 5 patients. When comparing the prevalence of AOD in
our medical ICU patients (39%) to the population preva-
lence of the city of Richmond (17.9%), the medical ICU
rate was significantly higher (p < 0.0001).
Baseline characteristics for patients are outlined in Table
3. Patients with AOD were more likely to be male.
Although one patient with AOD was intubated for delir-
ium tremens, analyses revealed no difference in reason for
MV between the two groups. Patients with AOD were less
severely ill as measured by APACHE II, and adjustment of
GCS suggested a trend toward lower severity of illness (p
= 0.07). The two groups had similar Sequential Organ
Failure Assessment (SOFA) scores on the first day of MV
and adjusting for GCS did not change the results.
Patients with AOD were significantly more likely to
receive benzodiazepines (27 out of 27 patients versus 39
out of 43, p = 0.044) and opioids (26 out of 27 patients
versus 31 out of 43, p = 0.006) compared to patients with-
out AOD. Administered opioids included morphine
(AOD 15 versus non-AOD 21, p = 0.38), fentanyl (AOD
13 versus non-AOD 16, p = 0.26), hydromorphone (AOD
3 versus non-AOD 0, p = 0.22), and meperidine (AOD 0
versus non-AOD 1, p = 0.39). There was a trend toward
increase methadone administration in the AOD group
(AOD 4 versus non-AOD 1, p = 0.07). The likelihood of
receiving propofol was similar in the two groups (12 out
of 27 versus 21 out of 43, p = 0.72). Table 4 summarizes
the administered sedative and opioid doses. The group of
patients with AOD received 2.5 times and 5 times the total
doses of benzodiazepines and opioids, respectively, com-
pared to the group without AOD. Propofol dose did not
differ in the two groups. While the number of continu-
ously infused sedatives and opioids was similar for AOD
and non-AOD patients (2.1 versus 1.8, p = 0.15), the
mean infusion duration in the AOD group was longer (16
hours/day.medication, 95%CI [12.7; 18.3] versus 10 [7.6;
12.1], p = 0.002).
A total of 2381 RASS values were recorded during 362
days of MV for the 70 study patients. The number of
assessments was similar between patients with and with-
out AOD (28 observations, IQR [16.0; 39.0] versus 30,
IQR [14.0; 40.2], p = 0.89). The mean RASS was similar
among AOD patients (-2; 95% CI [-2.6; -1.6]) and non-
AOD patients (-2; 95% CI [-2.4; -1.6], p = 0.83). However,
AOD patients had a larger variance in RASS (3 RASS units,
95%CI [2.3; 3.7] versus 2, 95%CI [1.5; 2.6], p = 0.049),
indicating larger fluctuations in sedation levels. Patients
with AOD were not more frequently agitated as measured
Table 2: Richmond Agitation-Sedation Scale
Score Term Description
+4 Combative Overtly combative or violent. Immediate danger to staff
+3 Very agitated Pulls on or removes tube(s) or catheter(s), or has aggressive behavior toward staff
+2 Agitated Frequent nonpurposeful movement or patient ventilator dyssynchrony
+1 Restless Anxious or apprehensive but movements not aggressive or vigorous
0 Alert and calm
-1 Drowsy Not fully alert, but has sustained (>10 seconds) awakenings, with eye contact, to voice
-2 Light sedation Briefly (<10 seconds) awakens with eye contact to voice
-3 Moderate sedation Any movement (but no eye contact) to voice
-4 Deep sedation No response to voice, but any movement to physical stimuli
-5 Unarousable No response to voice or physical stimulationBMC Anesthesiology 2007, 7:3 http://www.biomedcentral.com/1471-2253/7/3
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by RASS ≥ 3 compared to those without AOD (3.0% of
observations, 95%CI [2.1; 4.2]% versus 2.4%, 95%CI
[1.8; 3.2]%, p = 0.33).
AOD patients and non-AOD patients had similar MV
duration (3.6 days, 95%CI [2.60; 4.71] versus 3.9, 95%CI
[2.91; 5.14], p = 0.89) (Figure 2). Adjustment for gender,
APACHE II, lorazepam equivalents, morphine equiva-
lents, and duration of continuous infusions did not
change the results. Because mortality on MV may be more
a measure of time until death than outcome of mechani-
cal ventilation management, we analyzed MV duration for
ICU survivors and non-survivors. Twenty patients died in
the ICU, 6 with AOD and 14 without AOD. The median
duration of MV in non-survivors with AOD tended to be
shorter compared to ICU non-survivors without AOD
(AOD 3.6 days, 95% CI [0.43; undeterminable] versus
non-AOD 5.4 days, 95% CI [2.22; 10.25], p = 0.12). Sever-
ity of illness in the two groups was similar as measured by
APACHE II (AOD 32, 95% CI [23.7; 39.7] versus non-
AOD 31, 95% CI [26.0; 36.4], p = 0.92) and SOFA (AOD
12, 95% CI [8.0; 15.0] versus non-AOD 11, 95% CI [8.3;
12.9], p = 0.65). Adjustment of APACHE II for GCS (AOD
23, 95% CI [15.6; 30.8] versus non-AOD 23, 95% CI
[17.5; 27.5], p = 0.88) and adjustment of SOFA for GCS
(AOD 8, 95% CI [5.4, 11.6] versus non-AOD 7, 95% CI
[5.4; 9.5], p = 0.55) did not change severity of illness.
Fifty patients survived the ICU, 21 with AOD and 29 with-
out AOD. Duration of MV for ICU survivors was similar
for the two groups (AOD 3.8 days, 95% CI [2.36; 4.73]
versus non-AOD 3.4 days, 95% CI [2.35; 4.82], p = 0.87).
AOD patients who survived were less severely ill as meas-
ured by APACHE II (AOD 19, 95% CI [15.5; 22.3] versus
non-AOD 24, 95% CI [21.0; 26.7] p = 0.03) but not SOFA
(AOD 7, 95% CI [5.2; 8.2] versus non-AOD 8, 95% CI
[6.6; 9.1], p = 0.25). APACHE II adjusted for GCS
remained lower in the AOD group (AOD 11, 95% CI [8.2;
14.3] versus non-AOD 15, 95% CI [12.7; 17.9], p =
0.045). SOFA adjusted for GCS remained similar for the
AOD and non-AOD group (AOD 5, 95% CI [3.7; 5.8] ver-
sus non-AOD 4, 95% CI [2.8; 5.3], p = 0.40).
There was no difference in the rate of reintubation (11%
versus 9%, p = 0.81), tracheostomy (7% versus 2%, p =
0.31), or hospital mortality (22% versus 40%, p = 0.13).
ICU length of stay (6 days [3.4; 6.9] versus 6 days, 95% CI
[4.4; 6.8], p = 0.91) and hospital length of stay (9 days,
95%CI [5.3; 11.9] versus 13 days, 95%CI [9.7; 18.2], p =
0.11) were similar between patients with and without
AOD. There were no unplanned extubations.
Discussion
The current study reveals that nearly 40% of all mechani-
cally ventilated patients in our medical ICU suffer from
alcohol or other drug use disorders, with alcohol predom-
inating. Additionally, our study found that AOD patients
receive a greater amount of sedatives and opioids than
their non-AOD comparators in order to achieve a similar
degree of sedation. Despite this greater exposure to seda-
tives, the duration of MV was similar in the AOD and the
non-AOD groups.
AOD is a common problem in our medical ICU, affecting
27 out of 70 (39%) of our long-term mechanically venti-
lated patients. The true rate in our patient population is
likely to be even higher because of the retrospective nature
of our study and because clinicians fail to diagnose AOD
in 10% to 82% of patients [25,26]. Our rate is substan-
tially higher than that reported in the literature and may
be explained by methodological issues. Other studies
have examined rates of admissions directly attributable to
AOD or have limited diagnosis to alcohol use disorders
[9,10]. We included all patients where AOD was either a
primary or other diagnosis. The prevalence of AOD in our
mechanically ventilated patients was significantly higher
than that in the surrounding community, indicating that
patients with AOD are at increased risk of requiring MV.
This finding has also been demonstrated by others. Moss
et al. have shown that patients with alcohol use disorders
and sepsis are more likely to require MV compared to sep-
tic patients without alcohol use disorders [10]. Saitz et al.
have shown that patients with pneumonia who have alco-
hol use disorders are at increased risk of requiring ICU
level care, and Suchyta et al. have shown that patients with
AOD and other psychiatric disorders are overrepresented
among ICU patients [11,27].
Distribution of substances implicated in alcohol and other  drug use disorders Figure 1
Distribution of substances implicated in alcohol and other 
drug use disorders. Benzo/Barb: benzodiazepines or barbitu-
rates.
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Alcohol was the most commonly implicated substance,
which is similar to national findings, and our rate of 31%
among MV patients is similar to the 30% reported in a
prospective study by Moss et al [10]. Also consistent with
national findings, in 91% of all patients alcohol use disor-
ders, alcohol was the only substance implicated [8].
Among non-alcohol drug use disorders, cocaine and her-
oin, the two most common illicit drugs used in the city of
Richmond, were the most commonly implicated sub-
stances in our patient population (5 out of 7 patients)
[24]. Not surprisingly, no patient was diagnosed with
amphetamine use disorders, since these substances are
more commonly used in the Western part of the United
States than Virginia [28]. Additionally, the highest preva-
lence of amphetamine use disorders is in the age group
18–34 years old, which is generally younger than our
study population.
Patients with AOD required 2.5 times more sedative and
5 times more opioid doses to achieve sedation levels sim-
ilar to patients without AOD. They also received longer
duration of infusions which likely resulted in higher
plasma levels and suggest a high degree of tolerance [29].
Although no difference was seen in propofol dose, rela-
tively few patients received this sedative. Since sedation
was managed according to a standardized algorithm in
our ICU, it is not likely that the higher dosages seen in the
AOD patients were driven by a bias towards greater levels
of sedation in this population, but rather by the true need
to achieve a pre-specified level of sedation. This is further
supported by tolerance and increased metabolism
through induction of the cytochrome P-450 enzyme sys-
tem documented previously in this population [30].
Patients with AOD and those without AOD have similar
bilirubin and creatinine, suggesting that lower doses in
non-AOD patients are not accounted for by impaired
metabolism and clearance. Additionally, P/F and PEEP
were similar for both groups, suggesting no difference in
lung injury and need for sedation.
Patients with AOD had duration of MV similar to patients
without AOD. Patients without AOD had a higher
number of patients with pneumonia, acute lung injury
and sepsis, diagnoses that are associated with longer dura-
tion of mechanical ventilation [31]. It is possible that this
could have lead to a longer MV duration in the group of
Table 3: Baseline Characteristics
AOD No AOD p
n 27 43
Age (years) (mean [95% CI]) 50 [45.0; 55.8] 55 [50.6; 59.2] 0.20
Gender (n men/women) 21/6 15/28 <0.0001
Race (n African American/White/Asian) 20/7/0 22/19/2 0.12
APACHE II (mean [95% CI]) 22 [18.2; 25.2] 26 [23.5; 29.0] 0.048
APACHE II excluding GCS (mean [95% CI]) 13 [10.6; 17.1] 18 [15.1; 20.2] 0.07
SOFA (mean [95% CI]) 8 [6.3; 9.3] 9 [7.5; 9.9] 0.33
Bilirubin* (mg/dl) (mean [95% CI]) 2.2 [0.65; 3.85] 1.8 [0.52; 3.07] 0.65
Creatinine (mg/dl) (median, IQR) 1.1 [0.80; 2.20] 1.5 [1.10; 2.80] 0.10
P/F (mean [95% CI]) 225 [177.4; 272.8] 218 [181.5; 254.2] 0.81
PEEP (cm H2O) (mean [95% CI]) 5 [4.4; 6.4] 5 [3.9; 5.6] 0.30
Reason for mechanical ventilation 0.46
Pneumonia/ALI 4 9
Sepsis 1 4
Delirium/Neurologic 7 10
Asthma/COPD 3 4
Upper airway obstruction 4 3
Hemorrhagic shock 3 4
Cardiac 1 4
Cardiopulmonary arrest 1 2
Drug overdose 3 0
Other 0 3
AOD: alcohol and other drug use disorders
CI: confidence interval
APACHE II: Acute Physiology and Chronic Health Evaluation II
GCS: Glasgow Coma Score
SOFA: Sequential Organ Failure Assessment
*Bilirubin: Total bilirubin measured in 14 patients with AOD and 22 patients without AOD
IQR: Interquartile range
P/F: Partial pressure of oxygen divided by fraction of inspired oxygen
PEEP: Positive end expiratory pressureBMC Anesthesiology 2007, 7:3 http://www.biomedcentral.com/1471-2253/7/3
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patients without AOD. Additionally, patients without
AOD had higher severity of illness which may also have
resulted in longer duration of mechanical ventilation
compared to the group with AOD. It is conceivable that
patients with AOD did not have a shorter MV duration
because of the increased sedative and opioid requirement.
The longer expected MV duration in the group of patients
without AOD may have been eliminated by the increased
sedative and opioid requirements in patients with AOD,
resulting is similar MV duration in the 2 groups.
Our study has several strengths. The study was conducted
at a large urban medical center, and patients were ran-
domly selected. Diagnoses were established by clinical
experts in Addiction Medicine who were blinded to the
amount of administered sedatives and opioids and dura-
tion of MV. To minimize the bias in assigning an AOD
diagnosis retrospectively, toxicology data and healthcare
provider history were used whenever possible; when not
available, very strict adherence to the definitions of the
DSM IV-TR was established. Both sedation and weaning
from MV are standardized in our ICU, thus eliminating
the potential confounding effect of differential prefer-
ence-based practices in this area on the outcomes of inter-
est.
Our study has limitations. The diagnosis of AOD is diffi-
cult to establish in patients, and this is particularly prob-
lematic in non-verbal critically ill patients undergoing
MV. Screening for AOD is not standardized in our ICU
and is at the discretion of clinicians. In our experience,
intensivists do not routinely determine the presence of
these disorders in their patients. The definition of AOD is
broad and includes behavioral and social aspects, and cli-
nicians may focus on the aspects of physiologic depend-
ence, tolerance and withdrawal during critical illness.
Additionally, next-of-kin may not be forthcoming with
information about AOD. These factors contribute to the
underdiagnosis and misclassification of some study
patients. Despite this limitation, we were able to deter-
mine significant differences between patients assigned a
diagnosis of AOD and those not assigned this diagnosis,
indicating that patients with AOD are different from those
without AOD. The study sample was small; however, even
the small number of charts reviewed had sufficient power
to detect significant differences in the primary outcome,
again supporting the findings that patients with AOD are
quite different from their non-AOD counterparts. The
study was limited to a single center's medical ICU, exclud-
ing patients in the surgical ICU, patients with primarily
cardiac diagnoses, and trauma patients which may limit
its generalizability.
Conclusion
Our study is the first to identify AOD as an important
comorbidity that impacts sedation management while on
MV. AOD patients require a greater amount of sedatives
and opioids to achieve the same level of sedation. ICU cli-
Kaplan-Meier estimate of probability of remaining on  mechanical ventilation (MV) in patients with alcohol and  other drug use disorders (AOD) and those without (No  AOD) Figure 2
Kaplan-Meier estimate of probability of remaining on 
mechanical ventilation (MV) in patients with alcohol and 
other drug use disorders (AOD) and those without (No 
AOD).
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Table 4: Sedative and Opioid Doses
AOD No AOD p
Median IQR Median IQR
Lorazepam equivalents (mg/kg.day) 0.5 0.32–1.08 0.2 0.02–0.63 0.004
Morphine equivalents (mg/kg.day) 0.5 0.03–2.68 0.1 0.00–0.93 0.03
Propofol (microg/kg.day)* 0 0–28 0 0–14 0.81
AOD: alcohol and other drug use disorders
IQR: interquartile range
*33 patients received propofol, of which 12 had AODBMC Anesthesiology 2007, 7:3 http://www.biomedcentral.com/1471-2253/7/3
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nicians need to be cognizant of the potential influence of
AOD on the course and management of their mechani-
cally ventilated patients, particularly in those ICU's that
do not utilize a clinical practice guideline-driven sedation
protocol, in order to avoid potential complications asso-
ciated with over- or undersedation. Given a problem of
such an extensive magnitude, AOD among MV patients
needs to be studied further in prospective studies to gain
a better understanding of how to improve sedation and
other outcomes in these patients.
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